Candel Therapeutics Ownership

CADL Stock  USD 7.75  3.14  68.11%   
Candel Therapeutics holds a total of 32.48 Million outstanding shares. Candel Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Candel Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Candel Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Dividend Paid And Capex Coverage Ratio is expected to rise to -71.19 this year. The value of Common Stock Shares Outstanding is expected to slide to about 23.2 M. The value of Net Loss is expected to slide to about (17.8 M).
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.

Candel Stock Ownership Analysis

About 30.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.73. Candel Therapeutics had not issued any dividends in recent years. Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company was incorporated in 2003 and is based in Needham, Massachusetts. Candel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people. For more info on Candel Therapeutics please contact FOCIS MD at 617 916 5445 or go to https://www.candeltx.com.

Candel Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Candel Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Candel Therapeutics backward and forwards among themselves. Candel Therapeutics' institutional investor refers to the entity that pools money to purchase Candel Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Morgan Stanley - Brokerage Accounts2024-09-30
64.4 K
Hb Wealth Management, Llc2024-09-30
56.7 K
Charles Schwab Investment Management Inc2024-09-30
46.8 K
Bank Of New York Mellon Corp2024-09-30
45 K
Goldman Sachs Group Inc2024-09-30
30.3 K
Barclays Plc2024-09-30
28.7 K
Simplex Trading, Llc2024-09-30
22.8 K
Virtu Financial Llc2024-06-30
22.6 K
Rhumbline Advisers2024-09-30
22.5 K
Northpond Ventures, Llc2024-09-30
1.9 M
Vanguard Group Inc2024-09-30
946.3 K
Note, although Candel Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Candel Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Candel Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Candel Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Candel Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Benz Edward J. Jr 2 days ago
Acquisition by Benz Edward J. Jr of 14240 shares of Candel Therapeutics at 5.71 subject to Rule 16b-3
 
Aguilar-cordova Estuardo few days ago
Disposition of 1800 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 6.85 subject to Rule 16b-3
 
Aguilar-cordova Estuardo few days ago
Disposition of 20000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.23 subject to Rule 16b-3
 
Aguilar-cordova Estuardo over a week ago
Disposition of 20000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 4.46 subject to Rule 16b-3
 
Barone Francesca over a week ago
Disposition of 22081 shares by Barone Francesca of Candel Therapeutics at 4.5556 subject to Rule 16b-3
 
Aguilar-cordova Estuardo over two weeks ago
Disposition of 20000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 4.97 subject to Rule 16b-3
 
Tak Paul Peter over two weeks ago
Acquisition by Tak Paul Peter of 12900 shares of Candel Therapeutics at 1.55 subject to Rule 16b-3
 
Aguilar-cordova Estuardo over three weeks ago
Disposition of 7500 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.33 subject to Rule 16b-3
 
Aguilar-cordova Estuardo over a month ago
Disposition of 7500 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 4.92 subject to Rule 16b-3
 
Aguilar-cordova Estuardo over a month ago
Disposition of 7500 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.33 subject to Rule 16b-3
 
Aguilar-cordova Estuardo over a month ago
Disposition of 7500 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.27 subject to Rule 16b-3
 
Aguilar-cordova Estuardo over a month ago
Disposition of 7500 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.3 subject to Rule 16b-3

Candel Therapeutics Outstanding Bonds

Candel Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Candel Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Candel bonds can be classified according to their maturity, which is the date when Candel Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Candel Therapeutics Corporate Filings

8K
11th of December 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
6th of December 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
24th of May 2024
Other Reports
ViewVerify

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Candel Therapeutics is a strong investment it is important to analyze Candel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Candel Therapeutics' future performance. For an informed investment choice regarding Candel Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.73)
Revenue Per Share
0.001
Return On Assets
(0.52)
Return On Equity
(4.81)
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.